Title: Results of a Global Phase 3 Trial Comparing Oral Solithromycin versus Oral Moxifloxacin for Treatment of Community-acquired Bacterial Pneumonia (CABP) in Adults

Authors: David Oldach, Carlos Barrera, Analía Mykietiuk, Hristo Metev, Mimi Floarea Nitu, Najumuddin Karimjeee, Alexis Doreski, Ismail Mitha, Cristina Mihaela Tanaseanu, Joseph McDermott Molina, Yuri Antonovsky, Dirkie Johanna Van Rensburg, Brian H. Rowe, Jose Flores, Barbara Sokolowska, Kay Clark, Kara Keedy, Anita Das, Brian Jamieson, and Prabhavathi Fernandes

Objective: Despite guidelines for antibiotic stewardship, antibiotic resistance in CABP is a looming problem. This study compares solithromycin, a fourth generation macrolide and the first fluoroketolide, to moxifloxacin.

Methods: This was a double-blind, randomized controlled trial enrolling adults with CABP, PORT Risk Class II, III or IV (NCT#01756339). Patients were randomized 1:1 to oral solithromycin (5 days) or oral moxifloxacin (7 days), with evaluations at Baseline, Day 4 to assess early clinical response (ECR), Day 7, Day 12-17 (short-term follow-up, or SFU visit), and Day 28 (long-term follow-up). An early clinical response was defined as improvement in at least 2 of 4 cardinal symptoms (cough, chest pain, dyspnea, sputum production) without worsening in any. Success at SFU was determined by investigators. Primary objectives were demonstration of non-inferiority (10% NI margin) at ECR in the intent to treat (ITT) population (FDA guidance) and at SFU in the ITT and clinically evaluable (CE) populations (EMA guidance).

Results: 860 patients from 16 countries were randomized (ITT population); 856 received at least one dose of study drug (safety population); a microbiological diagnosis was established in 54% (mITT population); and 90% met key study inclusion and exclusion criteria without confounding diagnoses and within pre-specified protocol windows for follow-up (CE population). Mean age of solithromycin patients was 58.5 years, with 36.4% ≥ age 65, versus 56.7 years with 31.6% ≥ age 65 for moxifloxacin. 50.7% of solithromycin patients had PORT III/IV disease (11.3% PORT IV), versus 48.6% of moxifloxacin patients (8.8% PORT IV). Streptococcus pneumoniae was the most commonly diagnosed pathogen (23%), followed by Haemophilus influenzae (16%), Legionella pneumophila (15%), Mycoplasma pneumoniae (9%), Moraxella catarrhalis (6%), and Staphylococcus aureus (4%).

Solithromycin was non-inferior to moxifloxacin in the ITT in ECR (78.2% versus 77.9%) and SFU success (84.5% versus 86.6%) and in the CE-SFU success (88.1% versus 91.3%). Comparative ECR success for solithromycin was more favorable among the pre-defined sub-group of patients ≥ age 75 (83.9% vs 69.8%). Solithromycin demonstrated comparable safety to moxifloxacin in the occurrence of adverse events (AEs) (36.6% versus 35.6%), study-drug related AEs (10.1% versus 12.5%), Serious AEs (6.6% versus 6.3%; none attributed to study drug) and deaths (1.4% in both groups). Grade 4 ALTs (>8xULN) were observed in 5 moxifloxacin patients and 2 solithromycin patients. Two episodes of Clostridium difficile diarrhea were diagnosed, both in moxifloxacin recipients.

Conclusions: Oral solithromycin, the first fluoroketolide, was non-inferior to oral moxifloxacin for treatment of CABP, with greater relative success among older patients, despite treatment for 5 versus 7 days. Safety outcomes were comparable, although among moxifloxacin patients there were more Grade 4 ALT elevations and 2 episodes of C. difficile diarrhea. A return to macrolide monotherapy for CABP might be feasible in the future.